Androgen-deprivation Therapy

Drug Improves BMD, Lipids in ADT Recipients

ORLANDO—Toremifene increases bone mineral density (BMD) and improves lipid profiles in men receiving androgen deprivation therapy (ADT) for advanced prostate cancer, according to findings presented here at the third annual Prostate Cancer Symposium.

ADT Use Increasing

Despite widespread early detection and aggressive treatment for prostate cancer in the United States, the use of androgen deprivation therapy (ADT) has been increasing, researchers reported in BJU International (2006;98:973-978).

Next post in News